Article Text

Download PDFPDF
Cost effectiveness study
Cardiac resynchronisation therapy with an implantable cardioverter defibrillator appears to be cost-effective in patients with mild heart failure
  1. Keith Cooper
  1. University of Southampton, Southampton, UK
  1. Correspondence to : Dr Keith Cooper, University of Southampton, SHTAC, Epsilon House, Enterprise Road, Southampton, SO16 7NS, UK; kc{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


Cardiac resynchronisation therapy (CRT) resynchronises heart contractions using biventricular pacing and may be combined with an implantable cardioverter defibrillator (ICD); this combination is referred to as a CRT-defibrillator (CRT-D). Current clinical guidelines recommend the use of a CRT-D in patients with moderate to severe heart failure, reduced systolic function and ventricular conduction delay.1 Recent clinical trials have shown that CRT also improves outcomes in patients with mild heart failure,2 ,3 but the cost-effectiveness in these patients is unclear. Woo et al …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.